Table 2: Prior treatments.
Number of patients (%) | |
Adjuvant or neoadjuvant therapies | |
Anthracycline | 26 (41%) |
Taxane | 22 (35%) |
Trastuzumab | 19 (30%) |
Endocrine therapy | 21 (33%) |
Previous anti-HER2 therapies for metastatic breast cancer | |
Trastuzumab | 61 (97%) |
Pertuzumab | 41 (65%) |
Lapatinib | 21 (33%) |
Number of previous regimens for metastatic breast cancer | |
0 (first line) | 0 (0%) |
1 (second line) | 17 (27%) |
2 (third line) | 8 (13%) |
3 (forth line) | 12 (19%) |
≥ 4 | 26 (41%) |
Median time since first-line treatment of metastatic breast cancer, months (range) | 29 (6-217) |